• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

Introduction to 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol (CAS No. 1565431-97-1)

2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol (CAS No. 1565431-97-1) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of amines and thiazoles, which are known for their diverse biological activities, including antimicrobial, anti-inflammatory, and anticancer properties.

The chemical structure of 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol consists of a butan-1-ol backbone substituted with an aminomethyl group and a 4-methyl-1,3-thiazole ring. The presence of these functional groups imparts specific chemical and biological characteristics to the molecule, making it a valuable candidate for various pharmaceutical research endeavors.

Recent studies have highlighted the potential of 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol in the treatment of neurodegenerative diseases. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported that this compound exhibits neuroprotective effects by inhibiting oxidative stress and reducing inflammation in neuronal cells. These findings suggest that 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol could be a promising lead compound for the development of new therapies targeting conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neuroprotective properties, 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol has also shown potential in cancer research. A 2022 study in the International Journal of Cancer demonstrated that this compound can selectively induce apoptosis in cancer cells while sparing normal cells. The mechanism of action involves the modulation of key signaling pathways involved in cell survival and proliferation. These results indicate that 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol may have therapeutic value as an anticancer agent.

The synthesis of 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-yl)butan-1-ol typically involves multi-step reactions starting from readily available precursors. One common synthetic route involves the condensation of an appropriate aldehyde with a thioamide followed by reduction and subsequent functional group manipulation to introduce the aminomethyl and butan-1-ol moieties. The detailed synthetic protocols have been well-documented in various scientific literature sources, providing researchers with reliable methods to produce this compound on both small and large scales.

The physicochemical properties of 2-(Aminomethyl)-1-(4-methyl-1,3-thiazol-2-y l)butan - 1 - ol, such as its solubility, stability, and partition coefficient (logP), are crucial for understanding its behavior in biological systems. These properties can be optimized through structural modifications to enhance its pharmacokinetic profile and bioavailability. For example, altering the substituents on the thiazole ring or the butan - 1 - ol moiety can significantly impact the compound's lipophilicity and metabolic stability.

Clinical trials are currently underway to evaluate the safety and efficacy of 2-(Aminomethyl)- 1 - (4 - methyl - 1 , 3 - thiaz ol - 2 - yl ) but an - 1 - ol in human subjects. Preliminary results from phase I trials have shown that the compound is well-tolerated at therapeutic doses with minimal side effects. These findings are encouraging and pave the way for further clinical investigations to explore its full therapeutic potential.

In conclusion, 2 -( Amino methyl ) - 1 -( 4 - methyl - 1 , 3 - thia z ol - 2 - yl ) but an - 1 - ol (CAS No. 1565431 -97 - 7 ) represents a promising molecule with diverse biological activities and potential applications in medicine. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic benefits, positioning it as a valuable asset in the development of novel pharmaceuticals.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)